Patents by Inventor Atsuhiko Kubota
Atsuhiko Kubota has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8124780Abstract: A novel chemical compound useful as a therapeutic or prophylactic agent for acid-related diseases is provided, which has an excellent inhibitory effect against gastric acid secretion, an excellent effect of maintaining the inhibitory effect against gastric acid secretion, thereby maintaining intragastric pH high for a long time, and having more safety and appropriate physicochemical stability. Provided is a compound represented by where R1 and R3 may be the same or different and each represent a hydrogen atom or a C1-C6 alkyl group; R2 represents (5,5-dimethyl-1,3-dioxan-2-yl)methoxy group, 5,7-dioxaspiro[2.5]oct-6-ylmethoxy group, 1,5,9-trioxaspiro[5.5]undec-3-ylmethoxy group, or (2,2-dimethyl-1,3-dioxan-5-yl)methoxy group; R4, R5, R6 and R7 represent a hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 haloalkyl group, C1-C6 alkoxy group or C1-C6 haloalkoxy group; and W1 represents a single bond, methylene or ethylene group, a salt thereof or a solvate of these.Type: GrantFiled: August 11, 2008Date of Patent: February 28, 2012Assignee: Eisai R&D Management Co., Ltd.Inventors: Shuhei Miyazawa, Masanobu Shinoda, Tetsuya Kawahara, Nobuhisa Watanabe, Hitoshi Harada, Daisuke Iida, Hiroki Terauchi, Junichi Nagakawa, Hideaki Fujisaki, Atsuhiko Kubota, Masato Ueda
-
Patent number: 7781452Abstract: A compound represented by the following general formula (1), or a salt or hydrate thereof: [Formula 1] wherein R1 represents a C1-C6 alkyl group or C2-C6 alkynyl group which may be substituted, or a phenyl group which may be substituted, R2 represents a hydrogen atom or a C1-C6 alkyl group, R3 represents methyl or ethyl group, R4 represents a C1-C6 alkyl group, R5 represents a hydrogen atom, provided that a compound wherein R1 is a C1-C6 alkyl group unsubstituted or substituted with a halogen atom and R2 is a hydrogen atom is excluded.Type: GrantFiled: March 22, 2006Date of Patent: August 24, 2010Assignee: Eisai R&D Management Co., Ltd.Inventors: Shuhei Miyazawa, Hitoshi Harada, Hideaki Fujisaki, Atsuhiko Kubota, Kotaro Kodama, Junichi Nagakawa, Kiyoshi Oketani, Nobuhisa Watanabe
-
Publication number: 20090203911Abstract: A novel chemical compound useful as a therapeutic or prophylactic agent for acid-related diseases is provided, which has an excellent inhibitory effect against gastric acid secretion, an excellent effect of maintaining the inhibitory effect against gastric acid secretion, thereby maintaining intragastric pH high for a long time, and having more safety and appropriate physicochemical stability. Provided is a compound represented by where R1 and R3 may be the same or different and each represent a hydrogen atom or a C1-C6 alkyl group; R2 represents (5,5-dimethyl-1,3-dioxan-2-yl)methoxy group, 5,7-dioxaspiro[2.5]oct-6-ylmethoxy group, 1,5,9-trioxaspiro[5.5]undec-3-ylmethoxy group, or (2,2-dimethyl-1,3-dioxan-5-yl)methoxy group; R4, R5, R6 and R7 represent a hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 haloalkyl group, C1-C6 alkoxy group or C1-C6 haloalkoxy group; and W1 represents a single bond, methylene or ethylene group, a salt thereof or a solvate of these.Type: ApplicationFiled: August 11, 2008Publication date: August 13, 2009Inventors: Shuhei MIYAZAWA, Masanobu Shinoda, Tetsuya Kawahara, Nobuhisa Watanabe, Hitoshi Harada, Daisuke Iida, Hiroki Terauchi, Junichi Nagakawa, Hideaki Fujisaki, Atsuhiko Kubota, Masato Ueda
-
Patent number: 7538123Abstract: The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein R1 and R2 are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R3 represents a hydrogen atom or the like; and R6 represents a hydrogen atom or the like. This compound has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor, and is useful as an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage.Type: GrantFiled: May 11, 2005Date of Patent: May 26, 2009Assignee: Eisai R & D Management Co., Ltd.Inventors: Yuichi Suzuki, Koichi Ito, Atsushi Sasaki, Koshi Ueno, Miyuki Sakai, Hiroki Ishihara, Atsuhiko Kubota
-
Patent number: 7425634Abstract: An object of the present invention is to provide a novel chemical compound useful as a therapeutic or prophylactic agent for acid-related diseases, having an excellent inhibitory effect against gastric acid secretion, an excellent effect of maintaining the inhibitory effect against gastric acid secretion, thereby maintaining intragastric pH high for a long time, and having more safety and appropriate physicochemical stability. Provided is a compound represented by where R1 and R3 may be the same or different and each represent a hydrogen atom or a C1-C6 alkyl group; R2 represents (5,5-dimethyl-1,3-dioxan-2-yl)methoxy group, 5,7-dioxaspiro[2.5]oct-6-ylmethoxy group, 1,5,9-trioxaspiro[5.5]undec-3-ylmethoxy group, or (2,2-dimethyl-1,3-dioxan-5-yl)methoxy group; R4, R5, R6 and R7 represent a hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 haloalkyl group, C1-C6 alkoxy group or C1-C6 haloalkoxy group; and W1 represents a single bond, methylene or ethylene group, a salt thereof or a solvate of these.Type: GrantFiled: September 14, 2006Date of Patent: September 16, 2008Assignee: Eisai R&D Management Co., Ltd.Inventors: Shuhei Miyazawa, Masanobu Shinoda, Tetsuya Kawahara, Nobuhisa Watanabe, Hitoshi Harada, Daisuke Iida, Hiroki Terauchi, Junichi Nagakawa, Hideaki Fujisaki, Atsuhiko Kubota, Masato Ueda
-
Publication number: 20080119518Abstract: The present invention provides a compound represented by the formula (1) or a pharmacologically acceptable salt thereof, or a hydrate thereof (provided that a compound in which all of R4a, R4b, and R4c are hydrogen atoms is excluded.): [wherein R1 represents a hydrogen atom, R2 represents a hydrogen atom, R3 represents the formula: wherein R4a, R4b, and R4c are the same as or different from each other and each represents a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group, etc.Type: ApplicationFiled: February 2, 2006Publication date: May 22, 2008Inventors: Yuichi Suzuki, Koichi Ito, Atsushi Sasaki, Koshi Ueno, Daisuke Shinmyo, Miyuki Sakai, Hiroki Ishihara, Atsuhiko Kubota
-
Publication number: 20070219179Abstract: The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein R1 and R2 are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R3 represents a hydrogen atom or the like; and R6 represents a hydrogen atom or the like. This compound has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor, and is useful as an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage.Type: ApplicationFiled: May 11, 2005Publication date: September 20, 2007Inventors: Yuichi Suzuki, Koichi Ito, Atsushi Sasaki, Koshi Ueno, Miyuki Sakai, Hiroshi Ishihara, Atsuhiko Kubota
-
Publication number: 20070015782Abstract: An object of the present invention is to provide a novel chemical compound useful as a therapeutic or prophylactic agent for acid-related diseases, having an excellent inhibitory effect against gastric acid secretion, an excellent effect of maintaining the inhibitory effect against gastric acid secretion, thereby maintaining intragastric pH high for a long time, and having more safety and appropriate physicochemical stability. Provided is a compound represented by where R1 and R3 may be the same or different and each represent a hydrogen atom or a C1-C6 alkyl group; R2 represents (5,5-dimethyl-1,3-dioxan-2-yl)methoxy group, 5,7-dioxaspiro[2.5]oct-6-ylmethoxy group, 1,5,9-trioxaspiro[5.5]undec-3-ylmethoxy group, or (2,2-dimethyl-1,3-dioxan-5-yl)methoxy group; R4, R5, R6 and R7 represent a hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 haloalkyl group, C1-C6 alkoxy group or C1-C6 haloalkoxy group; and W1 represents a single bond, methylene or ethylene group, a salt thereof or a solvate of these.Type: ApplicationFiled: April 14, 2006Publication date: January 18, 2007Inventors: Shuhei Miyazawa, Masanobu Shinoda, Tetsuya Kawahara, Nobuhisa Watanabe, Hitoshi Harada, Daisuke Iida, Hiroki Terauchi, Junichi Nagakawa, Hideaki Fujisaki, Atsuhiko Kubota, Masato Ueda
-
Publication number: 20070010542Abstract: An object of the present invention is to provide a novel chemical compound useful as a therapeutic or prophylactic agent for acid-related diseases, having an excellent inhibitory effect against gastric acid secretion, an excellent effect of maintaining the inhibitory effect against gastric acid secretion, thereby maintaining intragastric pH high for a long time, and having more safety and appropriate physicochemical stability. Provided is a compound represented by where R1 and R3 may be the same or different and each represent a hydrogen atom or a C1-C6 alkyl group; R2 represents (5,5-dimethyl-1,3-dioxan-2-yl)methoxy group, 5,7-dioxaspiro[2.5]oct-6-ylmethoxy group, 1,5,9-trioxaspiro[5.5]undec-3-ylmethoxy group, or (2,2-dimethyl-1,3-dioxan-5-yl)methoxy group; R4, R5, R6 and R7 represent a hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 haloalkyl group, C1-C6 alkoxy group or C1-C6 haloalkoxy group; and W1 represents a single bond, methylene or ethylene group, a salt thereof or a solvate of these.Type: ApplicationFiled: September 14, 2006Publication date: January 11, 2007Inventors: Shuhei Miyazawa, Masanobu Shinoda, Tetsuya Kawahara, Nobuhisa Watanabe, Hitoshi Harada, Daisuke Iida, Hiroki Terauchi, Junichi Nagakawa, Hideaki Fujisaki, Atsuhiko Kubota, Masato Ueda
-
Publication number: 20060167041Abstract: A compound represented by the following general formula (1), or a salt or hydrate thereof: [Formula 1] wherein R1 represents a C1-C6 alkyl group or C2-C6 alkynyl group which may be substituted, or a phenyl group which may be substituted, R2 represents a hydrogen atom or a C1-C6 alkyl group, R3 represents methyl or ethyl group, R4 represents a C1-C6 alkyl group, R5 represents a hydrogen atom, provided that a compound wherein R1 is a C1-C6 alkyl group unsubstituted or substituted with a halogen atom and R2 is a hydrogen atom is excluded.Type: ApplicationFiled: March 22, 2006Publication date: July 27, 2006Inventors: Shuhei Miyazawa, Hitoshi Harada, Hideaki Fujisaki, Atsuhiko Kubota, Kotaro Kodama, Junichi Nagakawa, Kiyoshi Oketani, Nobuhisa Watanabe
-
Patent number: 7071201Abstract: A novel compound of the formula: wherein A, B, C, D, T, Y, and Z represent each methine or nitrogen; R1, R2, R3, R4, and R5 represent each a substituent; n represents 0 or an integer of 1 to 3; m represents 0 or an integer of 1 to 6; and p represents an integer of 1 to 3; and pharmacologically acceptable salts thereof. The compound has a serotonin antagonism and is clinically useful as medicament, in particular, for treating, ameliorating and preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.Type: GrantFiled: May 2, 2001Date of Patent: July 4, 2006Assignee: Eisai Co., Ltd.Inventors: Noritaka Kitazawa, Kohshi Ueno, Keiko Takahashi, Teiji Kimura, Atsushi Sasaki, Koki Kawano, Tadashi Okabe, Makoto Komatsu, Manabu Matsunaga, Atsuhiko Kubota
-
Publication number: 20050272764Abstract: A compound represented by the following general formula (1), or a salt or hydrate thereof: wherein R1 represents a C1-C6 alkyl group or C2-C6 alkynyl group which may be substituted, or a phenyl group which may be substituted, R2 represents a hydrogen atom or a C1-C6 alkyl group, R3 represents methyl or ethyl group, R4 represents a C1-C6 alkyl group, R5 represents a hydrogen atom, provided that a compound wherein R1 is a C1-C6 alkyl group unsubstituted or substituted with a halogen atom and R2 is a hydrogen atom is excluded.Type: ApplicationFiled: April 21, 2005Publication date: December 8, 2005Inventors: Shuhei Miyazawa, Hitoshi Harada, Hideaki Fujisaki, Atsuhiko Kubota, Kotaro Kodama, Junichi Nagakawa, Kiyoshi Oketani, Nobuhisa Watanabe
-
Publication number: 20050256103Abstract: The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein R1 and R2 are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R3 represents a hydrogen atom or the like; and R6 represents a hydrogen atom or the like. It is an object of the present invention to discover an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage, which has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor.Type: ApplicationFiled: May 11, 2005Publication date: November 17, 2005Inventors: Yuichi Suzuki, Koichi Ito, Atsushi Sasaki, Koshi Ueno, Miyuki Sakai, Hiroki Ishihara, Atsuhiko Kubota
-
Patent number: 6875761Abstract: Condensed pyridine compounds represented by formula (I): wherein: R1 and R3 are, independently, hydrogen, lower alkyl, or lower alkoxy; R2 represent an amino substituent; ring A is a benzene ring, pyridine ring, thiophene ring, or furan ring; and B represents a substituent containing a ring structure. Also, pharmaceutically acceptable salt and hydrates thereof. These compounds are clinically useful medicaments having serotonin antagonism, and in particular, for treating, ameliorating, or preventing spastic paralysis. They are also useful as central muscle relaxants for ameliorating myotonia.Type: GrantFiled: March 10, 2004Date of Patent: April 5, 2005Assignee: Eisai Co., Ltd.Inventors: Kohshi Ueno, Atsushi Sasaki, Koki Kawano, Tadashi Okabe, Noritaka Kitazawa, Keiko Takahashi, Noboru Yamamoto, Yuichi Suzuki, Manabu Matsunaga, Atsuhiko Kubota
-
Publication number: 20040255344Abstract: It is intended to provide an animal model of urinary dysfunction induced by damage in brain nerve tissue in a small animal conveniently and at a high reproducibility. A rat in which the central urinary function alone is specifically damaged by regionally injuring the brain superior colliculus with the use of a legion generator. The animal model of urinary dysfunction is useful in a method of screening a therapeutic agent for urinary dysfunction.Type: ApplicationFiled: April 2, 2004Publication date: December 16, 2004Inventors: Miyuki Sakai, Atsuhiko Kubota, Takahisa Hanada
-
Publication number: 20040204421Abstract: Condensed pyridine compounds represented by formula (I): 1Type: ApplicationFiled: March 10, 2004Publication date: October 14, 2004Applicant: Eisai Co., Ltd.Inventors: Kohshi Ueno, Atsushi Sasaki, Koki Kawano, Tadashi Okabe, Noritaka Kitazawa, Keiko Takahashi, Noboru Yamamoto, Yuichi Suzuki, Manabu Matsunaga, Atsuhiko Kubota
-
Patent number: 6790844Abstract: Condensed pyridine compounds represented by formula (I): wherein: R1 and R3 are, independently, hydrogen, halogen, lower alkyl, or lower alkoxy; R2 represents an amino substituent; ring A is a benzene ring, pyridine ring, thiophene ring, or furan ring; and B represents a substituent containing a ring structure. Also, pharmaceutically acceptable salt and hydrates thereof. These compounds are clinically useful medicaments having; serotonin antagonism, and in particular, for treating, ameliorating, or preventing spastic paralysis. They are also useful as central muscle relaxants for ameliorating myotonia.Type: GrantFiled: May 11, 2001Date of Patent: September 14, 2004Assignee: Eisai Co., LtdInventors: Kohshi Ueno, Atsushi Sasaki, Koki Kawano, Tadashi Okabe, Noritaka Kitazawa, Keiko Takahashi, Noboru Yamamoto, Yuichi Suzuki, Manabu Matsunaga, Atsuhiko Kubota
-
Patent number: 6579881Abstract: A 1,4-substituted cyclic amine derivative represented by the following formula or a pharmacologically acceptable salt thereof: wherein A, B, C, D, T, Y, and Z each represent a methine or a nitrogen linkage; R1, R2, R3, R4, and R5 each represent a substituent; n represents 0 or an integer of 1 to 3; m represents 0 or an integer of 1 to 6; and p represents an integer of 1 to 3. The compounds have serotonin antagonism. They are therefore clinically useful as medicaments, in particular, for treating, ameliorating, and preventing spastic paralysis. They are also useful as central muscle relaxants for ameliorating myotonia.Type: GrantFiled: May 18, 2001Date of Patent: June 17, 2003Assignee: Eisai Co., Ltd.Inventors: Noritaka Kitazawa, Kohshi Ueno, Keiko Takahashi, Teiji Kimura, Atsushi Sasaki, Koki Kawano, Tadashi Okabe, Makoto Komatsu, Manabu Matsunaga, Atsuhiko Kubota
-
Patent number: 6448243Abstract: A novel 1,4-substituted cyclic amine derivative represented by the following formula or a pharmacologically acceptable salt thereof: (wherein A, B, C, D, T, Y and Z represent each methine or nitrogen; R1, R2, R3, R4 and R5 represent each a substituent; n represents 0 or an integer of 1 to 3; m represents 0 or an integer of 1 to 6; and p represents an integer of 1 to 3.) The compound has a serotonin antagonism and is clinically useful as medicament, in particular, for treating, ameliorating and preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.Type: GrantFiled: August 11, 1999Date of Patent: September 10, 2002Assignee: Eisai Co., Ltd.Inventors: Noritaka Kitazawa, Kohshi Ueno, Keiko Takahashi, Teiji Kimura, Atsushi Sasaki, Koki Kawano, Tadashi Okabe, Makoto Komatsu, Manabu Matsunaga, Atsuhiko Kubota
-
Publication number: 20020086999Abstract: A novel 1,4-substituted cyclic amine derivative represented by the following formula: 1Type: ApplicationFiled: May 2, 2001Publication date: July 4, 2002Applicant: Eisai Co., Ltd.Inventors: Noritaka Kitazawa, Kohshi Ueno, Keiko Takahashi, Teiji Kimura, Atsushi Sasaki, Koki Kawano, Tadashi Okabe, Makoto Komatsu, Manabu Matsunaga, Atsuhiko Kubota